Conference
Phase 3 Study of First-Line Pembrolizumab ± Vibostolimab (anti-TIGIT) in Patients With PD-L1-Positive Metastatic NSCLC
Authors
Hellmann MD; Cho BC; Juergens R; Cheng Y; De Castro G; Erman M; Bauman JR; Takahashi T; Schwarzenberger P; Zhang P
Volume
16
Pagination
pp. S1010-S1011
Publisher
ELSEVIER SCIENCE INC
Publication Date
October 2021
Conference proceedings
JOURNAL OF THORACIC ONCOLOGY
Issue
10
ISSN
1556-0864